Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556998 · ClinicalTrials.gov registry record · Phase 2
A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents
A Phase 2 study of Pharmacokinetics, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 9
- Study locations
NCT00556998: Completed Phase 2 study of Pharmacokinetics, sponsored by Pfizer.
NCT00556998 is a Phase 2 study of Pharmacokinetics that has completed, run by Pfizer. The registered enrollment target is 26 participants, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (57% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00556998, a Phase 2 study of Pharmacokinetics, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.
Primary Outcome
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Conditions Studied
Interventions
- DRUG Voriconazole
Study Locations (9)
Tennessee
- Pfizer Investigational Site - Nashville
- Pfizer Investigational Site - Nashville
Texas
- Pfizer Investigational Site - Fort Worth
- Pfizer Investigational Site - Houston
Illinois
- Pfizer Investigational Site - Chicago
Louisiana
- Pfizer Investigational Site - New Orleans
North Carolina
- Pfizer Investigational Site - Durham
Ohio
- Pfizer Investigational Site - Cleveland
Oregon
- Pfizer Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00556998 record still lists
NCT00556998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 1 intervention - of which Voriconazole is the first listed.
NCT00556998 lists 9 locations in 7 states (Tennessee, Texas, Illinois).
Frequently Asked Questions
What is clinical trial NCT00556998 about?
NCT00556998 is a clinical study titled "A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents". This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.
What is the current status of trial NCT00556998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-06. Estimated completion is 2009-12.
What conditions does trial NCT00556998 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT00556998?
The interventions under investigation include: Voriconazole (DRUG).
Who is sponsoring clinical trial NCT00556998?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00556998 being conducted?
This trial has 9 study locations across Illinois, Louisiana, North Carolina, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00556998's enrollment target sits among peer trials
26 19th of 37 higher than 17 of 37 other Pharmacokinetics trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pharmacokinetics trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia